Company Overview and News

 
Opthea Doses Patients in Europe and Israel in Phase 2b Study of OPT-302 for Wet AMD

2018-03-27 globenewswire
MELBOURNE, Australia, March 27, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a developer of novel biologic therapies for the treatment of eye diseases, has dosed the first patients in Europe and Israel in the Company’s ongoing Phase 2b trial of OPT-302 for wet age-related macular degeneration (AMD). The study, which is a randomised, controlled clinical trial of OPT-302, a novel VEGF-C/D ‘Trap’ therapy, in combination with ranibizumab (Lucentis®) for wet AMD commenced dosing at clinical sites across the U.
Upvote Downvote

 
Opthea doses first patients in Europe and Israel in trial of macular degeneration treatment

2018-03-26 proactiveinvestors.com.au
Opthea Ltd (ASX:OPT) has dosed the first patients in Europe and Israel in its Phase 2b trial of OPT-302 for wet age-related macular degeneration (AMD).
Upvote Downvote

 
Opthea starts clinical trial for diabetic blindness treatment

2018-01-02 proactiveinvestors.com.au
Opthea Ltd (ASX:OPT) has started a clinical trial for its soluble VEGFR-3 ‘trap’ molecule OPT-302 in patients with centre-involved diabetic macular edema (DME).
Upvote Downvote

 
Opthea Presents Additional Positive Data from OPT-302 Phase 1/2a Wet AMD Trial at ASRS Meeting

2017-08-15 marketwired
MELBOURNE, AUSTRALIA--(Marketwired - Aug 15, 2017) - Opthea Limited (ASX: OPT), a developer of novel biologic therapies for the treatment of eye diseases, today announced further positive results from its Phase 1/2a clinical trial of OPT-302, a novel VEGF-C/D 'Trap' therapy for wet age-related macular degeneration (wet AMD). 
Upvote Downvote

 
Opthea to Present at the American Society of Retinal Specialists Annual Meeting and the Ophthalmology Innovation Summit

2017-08-09 marketwired
MELBOURNE, AUSTRALIA--(Marketwired - Aug 9, 2017) - Opthea Limited (ASX: OPT), a developer of novel biologic therapies for the treatment of eye diseases, announced today that the Company will present data from its Phase 1/2A clinical trial for its lead program OPT-302 in wet AMD at the 35th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) to be held August 11 -15, 2017.
Upvote Downvote

 
Opthea to Present at the Wedbush PacGrow Healthcare Conference

2017-08-07 marketwired
MELBOURNE, AUSTRALIA--(Marketwired - Aug 7, 2017) - Opthea Limited (ASX: OPT), a developer of novel biologic therapies for the treatment of eye diseases, today announced that the Company will be presenting at the 2017 Wedbush PacGrow Healthcare Conference taking place on August 15 - 16, 2017 at the Le Parker Meridien in New York, NY. Dr Megan Baldwin, Opthea's Chief Executive Officer will present at 8:00AM Eastern Time on Tuesday, August 15th 2017.
Upvote Downvote

 
Opthea Receives Notice of Allowance for Key Patent Covering OPT-302 in the United States

2017-07-06 marketwired
Opthea Limited (ASX: OPT), a developer of novel biologic therapies for the treatment of eye diseases, is pleased to announce that it has received a Notice of Allowance from the United States Patent and Trade Mark Office (USPTO) for the Company's Patent Application No. 14/768,701 for its OPT-302 soluble VEGFR-3 (sVEGFR-3) 'trap' molecule. Opthea anticipates the patent will be granted in the second half of 2017.
Upvote Downvote

 
Opthea Ltd secures notice of allowance for key U.S. patent

2017-07-06 proactiveinvestors.com.au
Opthea Ltd (ASX:OPT) has received a Notice of Allowance from the U.S. patent office for its OPT-302 soluble VEGFR-3 ‘trap’ molecule.
Upvote Downvote

 
Opthea Completes A$45 Million Capital Raising

2017-04-28 marketwired
MELBOURNE, AUSTRALIA--(Marketwired - Apr 28, 2017) - Opthea Limited (ASX: OPT) ("Opthea"), a developer of novel biologic therapies for the treatment of eye diseases, announced today the completion of its A$45 million capital raising launched on 3 April 2017. The proceeds from this offering enable the acceleration and diversification of the Company's clinical development strategy for OPT-302, its novel VEGF-C/D 'Trap' therapy for wet age-related macular degeneration ("wet AMD") and diabetic macular edema ("DME").
Upvote Downvote

 
Opthea raises $45M to advance novel therapy for eye diseases

2017-04-28 proactiveinvestors.com.au
Opthea (ASX:OPT) has completed a $45 million capital raising after receiving strong demand from international and domestic healthcare dedicated investment funds.
Upvote Downvote

 
Opthea reveals positive trial results; launches $45M equity raising

2017-04-03 proactiveinvestors.com.au
Opthea (ASX:OPT) has received positive results from its Phase 1/2A clinical trial of OPT-302, a novel therapy for wet age-related macular degeneration (wet AMD).
Upvote Downvote

 
Opthea Reports Positive Phase 1/2A Clinical Results for OPT-302 in wet AMD

2017-04-03 marketwired
Company to Host Conference Call Today at 10:30AM Australian Eastern Standard Time/8:30PM EDT (Sunday, April 2nd US)
Upvote Downvote

 
Opthea Conference Call/Webcast -- Update on OPT-302 Phase 1/2A Wet AMD Clinical Trial

2017-03-31 marketwired
MELBOURNE, AUSTRALIA--(Marketwired - Mar 31, 2017) - Opthea Limited (ASX : OPT), Opthea Limited, a developer of novel biologic therapies for the treatment of eye diseases, will host a conference call and webcast at 10:30am Australian Eastern Standard Time on Monday 3 April (8:30pm US EST on Sunday, April 2).
Upvote Downvote

 
Opthea receives positive feedback for macular degeneration therapy

2017-03-20 proactiveinvestors.com.au
Opthea (ASX:OPT) has received positive feedback from European regulatory agencies for the clinical development of OPT-302 for the treatment of wet age-related macular degeneration (wet AMD).
Upvote Downvote

 
Opthea Receives Positive Feedback from European Regulatory Agencies for the OPT-302 Clinical Program in wet AMD

2017-03-20 marketwired
MELBOURNE, AUSTRALIA--(Marketwired - Mar 20, 2017) - Opthea Limited (ASX: OPT), a developer of novel biologic therapies for the treatment of eye diseases, has concluded positive European scientific advice meetings with the United Kingdom's (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) and Sweden's Medical Products Agency (MPA) for the clinical development program of OPT-302, Opthea's novel VEGF-C/D 'Trap' therapy for the treatment of wet age-related macular degeneration (wet AMD).
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...